Faecal microbiota transfer in patients with microscopic colitis – a pilot study in collagenous colitis

References

• Munch A, Aust D, Bohr J, et al.; European Microscopic Colitis Group (EMCG). Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis. 2012;6:932–945.
   PubMed Web of Science ®Google Scholar
• Bohr J, Wickbom A, Hegedus A, et al. Diagnosis and management of microscopic colitis: current perspectives. Clin Exp Gastroenterol. 2014;7:273–284.
   PubMedGoogle Scholar
• Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations. United European Gastroenterol J. 2020. DOI:10.1177/2050640620951905
   Web of Science ®Google Scholar
• Munch A, Bohr J, Miehlke S, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut. 2016;65:47–56.
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109:449–455.
   PubMed Web of Science ®Google Scholar
• Fischer H, Holst E, Karlsson F, et al. Altered microbiota in microscopic colitis. Gut. 2015;64:1185–1186.
   PubMed Web of Science ®Google Scholar
• Carstens A, Dicksved J, Nelson R, et al. The gut microbiota in collagenous colitis shares characteristics with inflammatory bowel disease-associated dysbiosis. Clin Transl Gastroenterol. 2019;10:e00065.
   PubMed Web of Science ®Google Scholar
• Rindom Krogsgaard L, Kristian Munck L, Bytzer P, et al. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Scand J Gastroenterol. 2019;54:446–452.
   PubMed Web of Science ®Google Scholar
• Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479–493.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102–109e6.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110–118 e4.
   PubMed Web of Science ®Google Scholar
• Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611–619e6.
   PubMed Web of Science ®Google Scholar
• Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–916 e7.
   PubMed Web of Science ®Google Scholar
• Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67:2107–2115.
   PubMed Web of Science ®Google Scholar
• Holster S, Lindqvist CM, Repsilber D, et al. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clin Transl Gastroenterol. 2019;10:e00034.
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3:17–24.
   PubMed Web of Science ®Google Scholar
• Gunaltay S, Rademacher L, Hultgren Hornquist E, et al. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol. 2017;23:1319–1324.
   PubMed Web of Science ®Google Scholar
• Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14:1433–1438.
   PubMed Web of Science ®Google Scholar
• Louis P, Flint HJ. Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples. Appl Environ Microbiol. 2007;73:2009–2012.
   PubMed Web of Science ®Google Scholar
• Hjortswang H, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis. 2009;15:1875–1881.
   PubMed Web of Science ®Google Scholar
• Svedlund J, Sjodin I, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129–134.
   PubMed Web of Science ®Google Scholar
• Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–1052.
   PubMed Web of Science ®Google Scholar
• Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol. 1993;28:681–687.
   PubMed Web of Science ®Google Scholar
• Roth B, Bengtsson M, Ohlsson B. Diarrhoea is not the only symptom that needs to be treated in patients with microscopic colitis. Eur J Intern Med. 2013;24:573–578.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
   PubMed Web of Science ®Google Scholar
• Hjortswang H, Jarnerot G, Curman B, et al. The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol. 2006;41:1196–1203.
   PubMed Web of Science ®Google Scholar
• Stjernman H, Granno C, Jarnerot G, et al. Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn’s disease. Inflamm Bowel Dis. 2008;14:47–52.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Myrelid P. Årsrapport SWIBREG: SWIBREG Swedish Inflammatory Bowel Disease Registry; 2015.
   Google Scholar
• Nyhlin N, Wickbom A, Montgomery SM, et al. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2014;39:963–972.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–1736.
   PubMed Web of Science ®Google Scholar
• Kumawat AK, Strid H, Elgbratt K, et al. Microscopic colitis patients have increased proportions of Ki67(+) proliferating and CD45RO(+) active/memory CD8(+) and CD4(+)8(+) mucosal T cells. J Crohns Colitis. 2013;7:694–705.
   PubMed Web of Science ®Google Scholar
• Sundin J, Rangel I, Kumawat AK, et al. Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand J Gastroenterol. 2014;49:1068–1075.
   PubMed Web of Science ®Google Scholar
• Wilson BC, Vatanen T, Cutfield WS, et al. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:2.
   PubMed Web of Science ®Google Scholar
• König J, Brummer RJ. Faecal microbiota transplantation in IBS — new evidence for success? Nat Rev Gastroenterol Hepatol. 2020;17:199–200.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang B, Wu Y, et al. The value of fecal microbiota transplantation in the treatment of ulcerative colitis patients: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:5480961.
   PubMed Web of Science ®Google Scholar
• Burgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123:433–443.
   PubMed Web of Science ®Google Scholar
• Holster S, Hooiveld GJ, Repsilber D, et al. Allogenic faecal microbiota transfer induces immune-related gene sets in the colon mucosa of patients with irritable bowel syndrome. Biomolecules. 2019;9:586.
   Web of Science ®Google Scholar
• Killinger JM, Weintraub HS, Fuller BL. Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. J Clin Pharmacol. 1979;19:211–218.
   PubMed Web of Science ®Google Scholar
• Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321:156–164.
   PubMed Web of Science ®Google Scholar
• Sood A, Mahajan R, Singh A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13:1311–1317.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:1180–1199.
   PubMed Web of Science ®Google Scholar
• Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2011;9:881–890.
   PubMed Web of Science ®Google Scholar